Enerpac Tool
EPAC
Precision Drilling
PDS
Halozyme Therapeutics
HALO
4
Workday
WDAY
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
SLXN Silexion Therapeutics
- 1.190
- +0.070+6.25%
Close Mar 25 16:00 ET
- 1.200
- +0.010+0.84%
Post 19:50 ET
10.34MMarket Cap-0.13P/E (TTM)
1.200High1.120Low204.92KVolume1.160Open1.120Pre Close237.97KTurnover3.92%Turnover RatioLossP/E (Static)8.69MShares122.01852wk High-2.51P/B6.23MFloat Cap0.57552wk Low--Dividend TTM5.23MShs Float122.013Historical High--Div YieldTTM7.14%Amplitude0.575Historical Low1.161Avg Price1Lot Size
About Silexion Therapeutics Company
Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.
Company Profile
SymbolSLXN
Company NameSilexion Therapeutics
Listing DateApr 9, 2021
CEOMr. Ilan Hadar
MarketNASDAQ
Employees14
Fiscal Year Ends12-31
Address12 Abba Hillel Road
CityRamat-Gan
ProvinceTel Aviv
CountryIsrael
Zip Code5250606
Phone972-8-628-6005
Websitehttps://silexion.com
Company Executives
- Name
- Position
- Salary
- Ilan Hadar
- Chairman of the Board and Chief Executive Officer
- 1.54M
- Dr. Mitchell Shirvan
- Chief Scientific and Development Officer
- 1.30M
- Mirit Horenshtein Hadar
- Executive Vice President, Finance Affairs, Chief Financial Officer and Secretary
- 770.09K
- Ilan Levin
- Independent Director
- --
- Avner Lushi
- Independent Director
- 313.80K
- Professor Amnon Peled, PhD
- Independent Director
- --
- Shlomo Noy
- Independent Director
- 313.80K
- Ruth Alon
- Independent Director
- 45.00K
- Dror J. Abramov
- Independent Director
- 313.80K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings